The flu season is ramping up in a big way as an influenza A H3N2 mutation called subclade K drove a near 15% increase in clinical lab tests and a hospitalization rate of 11 people per 100,000, ...
In a phase I trial, an intranasal adjuvanted recombinant influenza vaccine appeared to result in response to a range of H5N1 clades. The adjuvanted vaccine elicited seroconversion against clade 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results